[Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts].
This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. Its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentin. Class II studies support the use of slow release valproic acid, clonazepam and oxycodone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentin or oxycodone, and the third choice are clonazepam or slow release valproic acid.
D000927:Anticonvulsants / Q000627:therapeutic use; D001938:Brazil; D003937:Diagnosis, Differential; D015259:Dopamine Agents / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D012148:Restless Legs Syndrome / Q000175:diagnosis* / Q000188:drug therapy*
D000927:Anticonvulsants; D015259:Dopamine Agents; D018491:Dopamine Agonists